Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US9834539 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
US10532047 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US11498913 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
US10414752 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
US10550098 | RIGEL PHARMS INC | Pyridin-2(1H)-one quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors |
Sep, 2035
(11 years from now) | |
US11497743 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase 1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
US10959994 | RIGEL PHARMS INC | Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
May, 2039
(15 years from now) | |
US11376246 | RIGEL PHARMS INC | Inhibiting mutant IDH-1 |
May, 2039
(15 years from now) | |
US11013734 | RIGEL PHARMS INC | Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation |
May, 2039
(15 years from now) | |
US11013733 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1) |
May, 2039
(15 years from now) | |
US11738018 | RIGEL PHARMS INC | Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1) |
Jul, 2039
(15 years from now) | |
US11723905 | RIGEL PHARMS INC | Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile |
Nov, 2039
(15 years from now) |
Rezlidhia is owned by Rigel Pharms Inc.
Rezlidhia contains Olutasidenib.
Rezlidhia has a total of 12 drug patents out of which 0 drug patents have expired.
Rezlidhia was authorised for market use on 01 December, 2022.
Rezlidhia is available in capsule;oral dosage forms.
Rezlidhia can be used as a method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation, a method of treating an adult patient with relapsed or refractory acute myeloid leukemia having a susceptible idh1 mutation, a method of treating a cancer where the cancer is acute myeloid leukemia (aml), a method of treating a cancer characterized by an idh1 mutation where the cancer is acute myeloid leukemia (aml).
Drug patent challenges can be filed against Rezlidhia from 01 December, 2026.
The generics of Rezlidhia are possible to be released after 12 November, 2039.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity(NCE) | Dec 01, 2027 |
Orphan Drug Exclusivity(ODE-413) | Dec 01, 2029 |
Drugs and Companies using OLUTASIDENIB ingredient
NCE-1 date: 01 December, 2026
Market Authorisation Date: 01 December, 2022
Treatment: A method of treating acute myeloid leukemia (aml) in patients with an isocitrate dehydrogenase-1 (idh1) mutation; A method of treating a cancer characterized by an idh1 mutation where the cancer is ac...
Dosage: CAPSULE;ORAL